Literature DB >> 26459662

New levodopa therapeutic strategies.

Peter A LeWitt1.   

Abstract

During its almost half-century of use for treating Parkinson's disease, levodopa therapy has permitted most patients to reverse much of this disorder's symptomatology. However, the full range of its therapeutic properties is not completely understood, as levodopa is showing itself to be more than just a metabolic intermediate for dopamine synthesis. Improving the constancy of drug delivery is the next frontier for enhancing therapeutic options with levodopa. Because conventional immediate-release carbidopa-levodopa tablets yield such variable pharmacokinetic profiles (as do other marketed products attempting to extend levodopa effect), improved formulations are greatly needed by patients experiencing motor fluctuations. Products under development or recently released in the U.S. include intestinal infusion, sustained-release microtablets, gastric-retentive formulations, a levodopa pro-drug, and methods for delivery of the drug by inhalation or subcutaneous infusion.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Drug delivery; Levodopa; Parkinson disease; Pharmacotherapy

Mesh:

Substances:

Year:  2015        PMID: 26459662     DOI: 10.1016/j.parkreldis.2015.09.021

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  10 in total

1.  Assessment of Duodopa® effects on quality of life of patients with advanced Parkinson's disease and their caregivers.

Authors:  Rosella Ciurleo; Francesco Corallo; Lilla Bonanno; Viviana Lo Buono; Giuseppe Di Lorenzo; Roberta Versaci; Cettina Allone; Rosanna Palmeri; Placido Bramanti; Silvia Marino
Journal:  J Neurol       Date:  2018-06-27       Impact factor: 4.849

2.  Gait initiation is impaired in subjects with Parkinson's disease in the OFF state: Evidence from the analysis of the anticipatory postural adjustments through wearable inertial sensors.

Authors:  Gianluca Bonora; Martina Mancini; Ilaria Carpinella; Lorenzo Chiari; Fay B Horak; Maurizio Ferrarin
Journal:  Gait Posture       Date:  2016-10-31       Impact factor: 2.840

3.  Locomotor differences in mice expressing wild-type human α-synuclein.

Authors:  Genesys Giraldo; Mieu Brooks; Benoit I Giasson; Christopher Janus
Journal:  Neurobiol Aging       Date:  2018-02-06       Impact factor: 4.673

4.  Regional Downregulation of Dopamine Receptor D1 in Bilateral Dorsal Lateral Geniculate Nucleus of Monocular Form-Deprived Amblyopia Models.

Authors:  Dongyue Lin; Zhonghao Wang; Wei Chen; Tao Shen; Xuan Qiu; Kun Wei; Jiahui Li; Dongsheng Yang; Ping Wang; Xuri Li; Jianhua Yan; Zhongshu Tang
Journal:  Front Neurosci       Date:  2022-06-08       Impact factor: 5.152

Review 5.  An update on pharmacological treatment options for amblyopia.

Authors:  Aldo Vagge; Lorenzo Ferro Desideri; Carlo Enrico Traverso
Journal:  Int Ophthalmol       Date:  2020-08-07       Impact factor: 2.031

Review 6.  Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedside.

Authors:  Sten-Magnus Aquilonius; Dag Nyholm
Journal:  Ups J Med Sci       Date:  2017-03-03       Impact factor: 2.384

7.  Pituitary adenylate cyclase-activating polypeptide (PACAP) has a neuroprotective function in dopamine-based neurodegeneration in rat and snail parkinsonian models.

Authors:  Gabor Maasz; Zita Zrinyi; Dora Reglodi; Dora Petrovics; Adam Rivnyak; Tibor Kiss; Adel Jungling; Andrea Tamas; Zsolt Pirger
Journal:  Dis Model Mech       Date:  2016-12-22       Impact factor: 5.758

8.  Development and Characterisation of Gastroretentive Solid Dosage Form Based on Melt Foaming.

Authors:  Gábor Vasvári; Ádám Haimhoffer; László Horváth; István Budai; György Trencsényi; Monika Béresová; Csaba Dobó-Nagy; Judit Váradi; Ildikó Bácskay; Zoltán Ujhelyi; Pálma Fehér; Dávid Sinka; Miklós Vecsernyés; Ferenc Fenyvesi
Journal:  AAPS PharmSciTech       Date:  2019-08-19       Impact factor: 3.246

Review 9.  Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.

Authors:  Daniel Garbin Di Luca; Nikolai Gil D Reyes; Susan H Fox
Journal:  Drugs       Date:  2022-07-16       Impact factor: 11.431

Review 10.  Gut Microbiota Approach-A New Strategy to Treat Parkinson's Disease.

Authors:  Jing Liu; Fei Xu; Zhiyan Nie; Lei Shao
Journal:  Front Cell Infect Microbiol       Date:  2020-10-22       Impact factor: 5.293

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.